Physician profile
Stephen B James
NPI 1013904697
$127,301.07
in general payments reported to CMS, 2019-2025
6 companies · $7,460 in 2025
The $7,460 reported for 2025 was more than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $21K · 2021: $20K · 2022: $92.40 · 2023: $47K · 2024: $18K · 2025: $7,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $66K · Travel and Lodging: $4,611 · Food and Beverage: $1,438 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $65,536.00 |
| Travel and Lodging | $4,611.05 |
| Food and Beverage | $1,438.04 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineart Sa | $65,536.00 | 2023-2025 | Cure Acpv2 - Anterior Cervical Plate, Talos T (Ha) - Transforaminal Ha Cage, Cure LP - Anterior Lumbar Plate |
| Medical Investment Advisors LLC | $54,600.41 | 2019-2021 | |
| Spineart USA INC | $7,075.33 | 2022-2023 | Perla C, Perla Tl, Talos |
| Boston Scientific Corporation | $38.53 | 2021-2023 | |
| Vgi Medical, LLC | $32.84 | 2022 | |
| Abbvie INC. | $17.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.